Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Myron Levin
University of Colorado Denver, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
GlaxoSmithKline
Payment for services (e.g., consulting fees, honoraria, paid authorship)
A description of how the financial interest relates to the NIH-funded research and why the Institution determined that the financial interest conflicts with such research:
Dr. Myron Levin has a significant financial interest due to his role as an Inventor/Intellectual Property Rights Owner with Merck and Co. Inc. and due to his role as a consultant for GSK.*
Dr. Adriana Weinberg has a significant financial interest due to her husband’s, Myron Levin, role as an Inventor/Intellectual Property Rights Owner with Merck and Co. Inc. and due to Dr. Levin’s role as a consultant for GSK.*
Dr. Adriana Weinberg is the PI on NIH grant 1 U01 AI141919-01 and protocol 18-0580 titled Persistence of Protection Conferred By Shingrix Against Herpes Zoster In Older Adults
Dr. Myron Levin is the MPI on this grant and the study.
See Attached File
PERSISTENCE OF PROTECTION CONFERRED BY SHINGRIX AGAINST HERPES ZOSTER IN OLDER ADULTS
Narrative There are two vaccines to prevent shingles in older people. One of these works much better. This study measures many aspects of how the human body responds to these vaccines and is able to resist shingles. This should help us understand what makes a vaccine better. The lessons learned may be valuable for improving other vaccines for older people.
Filed on March 18, 2019.
Tell us what you know about Myron Levin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Myron Levin filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Myron Levin | University of Colorado Denver | Conflict of Interest | GlaxoSmithKline | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.